CorMedix Inc., a pharmaceutical company focused on therapeutic products to treat cardiorenal disease, has completed patient enrollment for the phase II study of its oral drug candidate CRMD001.

CorMexix’ study of CRMD001 is to determine its efficacy in reducing the occurrence of Contrast-Induced Acute Kidney Injury (CI-AKI) and associated complications, with specific evaluation on the safety and efficacy of CRMD001 on biomarkers of acute kidney injury and kidney function.

CI-AKI, also referred to as Contrast Induced Nephropathy (CIN), affects approximately one-third of about 325,000 high risk patients with Chronic Kidney Disease in the United States who undergo angiography for vascular imaging. Complications can arise when iodinated contrast media is used in X-ray procedures to provide visual assessment of the status of blood vessels in different parts of the body.

The double blind, placebo-controlled, randomized study will be conducted in high risk patients who have CKD and that are currently receiving coronary angiography.

CorMedix president and CEO John C. Houghton noted that to-date there is no U.S. Food and Drug Administration-approved therapeutic treatment to prevent CI-AKI on the market. The current standard of care to prevent CI-AKI is to maintain hydration and to avoid nephrotoxic drugs.

CorMedix said it expects to report final results before year-end.

For more information visit